BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND DAXX, BING2, 1616, ENSG00000206206, MGC126246, Q9UER7, MGC126245, DAQB-126H3_2, DAP6
60998 results:

  • 1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
    Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
    Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
    Lin Y; Xu G; Li L; Xiang J; Zhai L
    Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. prostate intra-fraction motion recorded by transperineal ultrasound.
    Ballhausen H; Belka C; Li M
    Sci Data; 2024 May; 11(1):504. PubMed ID: 38755158
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. When to reinvite initially ineligible populations for targeted lung cancer screening?
    Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Determinants and Factors of Physical Activity After Oncology Treatments (DEFACTO) in Metropolitan France: Protocol of a Mixed Methods Study and Intervention.
    Aumaitre A; Gagnayre R; Foucaut AM
    JMIR Res Protoc; 2024 May; 13():e52274. PubMed ID: 38753415
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed prostate cancer.
    Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
    JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
    Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
    JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score.
    Baudewyns A; Guenzel K; Halinski A; Dariane C; Delavar G; Anract J; Barry Delongchamps N; Jabbour T; Bourgeno HA; Lefebvre Y; Ferriero M; Simone G; Fourcade A; Fournier G; Oderda M; Gontero P; Bernal-Gomez A; Mastrorosa A; Roche JB; Zahr RA; Ploussard G; Fiard G; Rysankova K; Bui AP; Taha F; Windisch O; Benamran D; Vlahopoulos L; Assenmacher G; Roumeguère T; Peltier A; Diamand R
    World J Urol; 2024 May; 42(1):322. PubMed ID: 38747982
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A novel model incorporating quantitative contrast-enhanced ultrasound into PI-RADSv2-based nomogram detecting clinically significant prostate cancer.
    Huang K; Luo L; Hong R; Zhao H; Li Y; Jiang Y; Feng Y; Fu Q; Zhou H; Li F
    Sci Rep; 2024 May; 14(1):11083. PubMed ID: 38745087
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Diabetes-related risk factors and survival among individuals with type 2 diabetes and breast, lung, colorectal, or prostate cancer.
    Laurberg T; Witte DR; Gudbjörnsdottir S; Eliasson B; Bjerg L
    Sci Rep; 2024 May; 14(1):10956. PubMed ID: 38740921
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
    Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
    Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Projected estimates of cancer in Canada in 2024.
    Brenner DR; Gillis J; Demers AA; Ellison LF; Billette JM; Zhang SX; Liu JL; Woods RR; Finley C; Fitzgerald N; Saint-Jacques N; Shack L; Turner D;
    CMAJ; 2024 May; 196(18):E615-E623. PubMed ID: 38740416
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Digital Adoption by an Organization Supporting Informal Caregivers During COVID-19 Pandemic Showing Impact on Service Use, Organizational Performance, and Carers' Well-Being: Retrospective Population-Based Database Study With Embedded User Survey.
    Szczepura A; Khan AJ; Wild D; Nelson S; Woodhouse S; Collinson M
    JMIR Aging; 2024 May; 7():e46414. PubMed ID: 38739915
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Anorectal function and symptoms 6 months after robot-assisted laparoscopic radical prostatectomy: a single-center study.
    Psarias T; Walter S; Holmbom M; Khayoun Issa I; Abdul-Sattar Aljabery F; Hallböök O
    Scand J Urol; 2024 May; 59():104-108. PubMed ID: 38738961
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
    Scilipoti P; Liedberg F; Garmo H; Wilberg Orrason A; Stattin P; Westerberg M
    Scand J Urol; 2024 May; 59():98-103. PubMed ID: 38738332
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Inhibition of prostate cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of Akt and Activation of AMPK Signaling.
    Nadile M; Sze NSK; Fajardo VA; Tsiani E
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732504
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. CYP7B1 as a Biomarker for prostate cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in prostate cancer Patients-Diamond Study).
    Russo GI; Durukan E; Asmundo MG; Lo Giudice A; Salzano S; Cimino S; Rescifina A; Fode M; Abdelhameed AS; Caltabiano R; Broggi G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731981
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on cancer Cell Lines.
    Albani M; Fassi EMA; Moretti RM; Garofalo M; Montagnani Marelli M; Roda G; Sgrignani J; Cavalli A; Grazioso G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731842
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A cross-sectional study of ERG expression and the relationship with clinicopathological features of prostate cancer in Southwestern Uganda.
    Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
    Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from prostate cancer Patients.
    Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
    Cells; 2024 May; 13(9):. PubMed ID: 38727318
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3050.